Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial
A postoperative autologous blood patch (ABP) intervention trial for patients who underwent lung resection for cancer to examine its effectiveness in preventing a prolonged air leak. AIM 1: To determine the safety and efficacy of autologous blood patch (ABP) as a means to reduce the rate of prolonged air leak (PAL) after lung cancer resection AIM 2: To prospectively examine variation in morbidity and quality of life between patients with and without a PAL
Checked against the public recordLast updated Oct 10, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Rush University Medical Center
- Interventions being studied
- Procedure: Autologous Blood Patch; Procedure: Standard of Care (per Physician)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients who underwent elective wedge resection, segmentectomy, lobectomy, or bilobectomy for suspected non-small cell lung cancer * Patients that have reviewed and signed the Informed Consent Form, had an opportunity to ask questions, and consent to have their de-identified data included in the study * Patients who have an air leak on the morning of postoperative Day 3 * Age ≥18 years old Exclusion Criteria: * Patients who undergo pneumonectomy, sleeve lobectomy, chest wall or diaphragm resection, or bilateral procedures. * Age \< 18 years old * Women who are pregnant
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Rush University Medical CenterChicago, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 10, 2025. Always confirm current availability with the study team.